BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 17961876)

  • 1. The immunogenicity and reactogenicity of DTPw-HBV/Hib 2.5 combination vaccine: results from four phase III multicenter trials across three continents.
    Ortega-Barrìa E; Kanra G; Leroux G; Bravo L; Safary A; Lefevre I;
    Vaccine; 2007 Dec; 25(50):8432-40. PubMed ID: 17961876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.
    Gatchalian S; Palestroque E; De Vleeschauwer I; Han HH; Poolman J; Schuerman L; Dobbelaere K; Boutriau D
    Int J Infect Dis; 2008 May; 12(3):278-88. PubMed ID: 17981067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new DTPw-HBV/Hib vaccine is immunogenic and safe when administered according to the EPI (Expanded Programme for Immunization) schedule and following hepatitis B vaccination at birth.
    Gatchalian S; Reyes M; Bernal N; Lefevre I; David MP; Han HH; Bock HL; Wolter J; Schuerman L
    Hum Vaccin; 2005; 1(5):198-203. PubMed ID: 17012860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical experience with DTPw-HBV and DTPw-HBV/Hib combination vaccines.
    Prymula R; Plisek S
    Expert Opin Biol Ther; 2008 Apr; 8(4):503-13. PubMed ID: 18352853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, dose-ranging assessment of the immunogenicity and safety of a booster dose of a combined diphtheria-tetanus-whole cell pertussis-hepatitis B-inactivated poliovirus-Hemophilus influenzae type b (DTPw-HBV-IPV/Hib) vaccine vs. co-administration of DTPw-HBV/Hib and IPV vaccines in 12 to 24 months old Filipino toddlers.
    Quiambao B; Van Der Meeren O; Kolhe D; Gatchalian S
    Hum Vaccin Immunother; 2012 Mar; 8(3):347-54. PubMed ID: 22330958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity, reactogenicity and safety of three-dose primary and booster vaccination with combined diphtheria-tetanus-whole-cell pertussis-hepatitis B-reduced antigen content Haemophilus influenzae type b vaccine in Filipino children.
    Gatchalian SR; Ramakrishnan G; Bock HL; Lefevre I; Jacquet JM
    Hum Vaccin; 2010 Aug; 6(8):664-72. PubMed ID: 20657177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Four is better than nine. a combined diphtheria-tetanus-pertussis-hepatitis B-Haemophilus influenzae type b vaccine for routine immunization in Malaysia.
    Wong SL; Soosai P; Teoh YL; Han HH; Lefevre I; Bock HL
    Southeast Asian J Trop Med Public Health; 2008 May; 39(3):474-83. PubMed ID: 18564687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new DTPw-HBV/Hib vaccine: immune memory after primary vaccination and booster dosing in the second year of life.
    Gatchalian S; Reyes M; Bermal N; Chandrasekaran V; Han HH; Bock HL; Lefevre I
    Hum Vaccin; 2008; 4(1):60-6. PubMed ID: 18376148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and reactogenicity of two regimens of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio and Haemophilus influenzae type b vaccines administered to infants primed at birth with hepatitis B vaccine.
    Cheng HK; Rajadurai VS; Amin Z; Sriram B; Yee MF; Han HH; Bock HL; Safary A
    Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):685-92. PubMed ID: 15689088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new DTPw-HB/Hib combination vaccine for primary and booster vaccination of infants in Latin America.
    Tregnaghi M; López P; Rocha C; Rivera L; David MP; Rüttimann R; Schuerman L
    Rev Panam Salud Publica; 2006 Mar; 19(3):179-88. PubMed ID: 16640847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa.
    Vesikari T; Rivera L; Korhonen T; Ahonen A; Cheuvart B; Hezareh M; Janssens W; Mesaros N
    Hum Vaccin Immunother; 2017 Jul; 13(7):1505-1515. PubMed ID: 28340322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and reactogenicity of combined versus separately administered DTPw-HBV and Hib vaccines given to healthy infants at 2, 4 and 6 months of age, with a booster at 18 months.
    Riedemann S; Reinhardt G; Jara J; Rios R; Wenzel MS; Willems P; Bock HL
    Int J Infect Dis; 2002 Sep; 6(3):215-22. PubMed ID: 12718838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib).
    Martinón-Torres F; Boisnard F; Thomas S; Sadorge C; Borrow R;
    Vaccine; 2017 Jun; 35(30):3764-3772. PubMed ID: 28583305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age.
    Halperin SA; Tapiero B; Diaz-Mitoma F; Law BJ; Hoffenbach A; Zappacosta PS; Radley D; McCarson BJ; Martin JC; Brackett LE; Boslego JW; Hesley TM; Bhuyan PK; Silber JL
    Vaccine; 2009 Apr; 27(19):2540-7. PubMed ID: 19124057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immunogenicity and safety of a reduced PRP-content DTPw-HBV/Hib vaccine when administered according to the accelerated EPI schedule.
    Chatterjee S; Rego SJ; D'Souza F; Bhatia BD; Collard A; Datta SK; Jacquet JM
    BMC Infect Dis; 2010 Oct; 10():298. PubMed ID: 20950457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactogenicity and immunogenicity profiles of a novel pentavalent diphtheria-tetanus-whole cell pertussis-hepatitis B and Haemophilus influenzae type B vaccine: a randomized dose-ranging trial of the Hib tetanus-conjugate content.
    Hla KH; Thein SA; Aye A; Han HH; Bock HL; David MP; Schuerman L
    Pediatr Infect Dis J; 2006 Aug; 25(8):706-12. PubMed ID: 16874170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary and booster vaccination in Latin American children with a DTPw-HBV/Hib combination: a randomized controlled trial.
    Espinoza F; Tregnaghi M; Gentile A; Abarca K; Casellas J; Collard A; Lefevre I; Jacquet JM
    BMC Infect Dis; 2010 Oct; 10():297. PubMed ID: 20950456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal non-typeable Hemophilus influenzae protein D conjugate vaccine (PHiD-CV) when co-administered with the DTPw-HBV/Hib vaccine in Indian infants: a single-blind, randomized, controlled study.
    Lalwani S; Chatterjee S; Chhatwal J; Verghese VP; Mehta S; Shafi F; Borys D; Moreira M; Schuerman L
    Hum Vaccin Immunother; 2012 May; 8(5):612-22. PubMed ID: 22634448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and reactogenicity of a combined fully liquid DTPw-HepB-Hib pentavalent vaccine in healthy infants: no clinically relevant impact of a birth dose of hepatitis B vaccine.
    Gentile A; Umido V; Czerniuk P; Nacul J; Seigelchifer M; Hilbert AK; Yela U; Herzog C; Aeberhard U; Spyr C
    Int J Infect Dis; 2011 Jan; 15(1):e24-9. PubMed ID: 21093342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa-IPV-HBV-Hib combination vaccine in healthy infants.
    Olivier C; Belohradsky BH; Stojanov S; Bonnet E; Petersen G; Liese JG
    Vaccine; 2008 Jun; 26(25):3142-52. PubMed ID: 18502545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.